Soluble Transferrin Receptor as Iron Deficiency Biomarker : Impact on Exercise Capacity in Heart Failure Patients
The soluble transferrin receptor (sTfR) is a marker of tissue iron status, which could indicate an increased iron demand at the tissue level. The impact of sTfR levels on functional capacity and quality of life (QoL) in non-anemic heart failure (HF) patients with otherwise normal systemic iron status has not been evaluated. We conducted an observational, prospective, cohort study of 1236 patients with chronic HF. We selected patients with normal hemoglobin levels and normal systemic iron status. Tissue iron deficiency (ID) was defined as levels of sTfR > 75th percentile (1.63 mg per L). The primary endpoints were the distance walked in the 6 min walking test (6MWT) and the overall summary score (OSS) of the Minnesota Living with Heart Failure Questionnaire (MLHFQ). The final study cohort consisted of 215 patients. Overall QoL was significantly worse (51 ± 27 vs. 39 ± 20, p-value = 0.006, respectively), and the 6 MWT distance was significantly worse in patients with tissue ID when compared to patients without tissue ID (206 ± 179 m vs. 314 ± 155, p-value < 0.0001, respectively). Higher sTfR levels, indicating increased iron demand, were associated with a shorter distance in the 6 MWT (standardized β = -0.249, p < 0.001) and a higher MLHFQ OSS (standardized β = 0.183, p-value = 0.008). In this study, we show that in patients with normal systemic iron parameters, higher levels of sTfR are strongly associated with an impaired submaximal exercise capacity and with worse QoL.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Journal of personalized medicine - 13(2023), 8 vom: 21. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ras-Jiménez, Maria Del Mar [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 27.08.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jpm13081282 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361217803 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361217803 | ||
| 003 | DE-627 | ||
| 005 | 20231226084656.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jpm13081282 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1204.xml |
| 035 | |a (DE-627)NLM361217803 | ||
| 035 | |a (NLM)37623532 | ||
| 035 | |a (PII)1282 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ras-Jiménez, Maria Del Mar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Soluble Transferrin Receptor as Iron Deficiency Biomarker |b Impact on Exercise Capacity in Heart Failure Patients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 27.08.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The soluble transferrin receptor (sTfR) is a marker of tissue iron status, which could indicate an increased iron demand at the tissue level. The impact of sTfR levels on functional capacity and quality of life (QoL) in non-anemic heart failure (HF) patients with otherwise normal systemic iron status has not been evaluated. We conducted an observational, prospective, cohort study of 1236 patients with chronic HF. We selected patients with normal hemoglobin levels and normal systemic iron status. Tissue iron deficiency (ID) was defined as levels of sTfR > 75th percentile (1.63 mg per L). The primary endpoints were the distance walked in the 6 min walking test (6MWT) and the overall summary score (OSS) of the Minnesota Living with Heart Failure Questionnaire (MLHFQ). The final study cohort consisted of 215 patients. Overall QoL was significantly worse (51 ± 27 vs. 39 ± 20, p-value = 0.006, respectively), and the 6 MWT distance was significantly worse in patients with tissue ID when compared to patients without tissue ID (206 ± 179 m vs. 314 ± 155, p-value < 0.0001, respectively). Higher sTfR levels, indicating increased iron demand, were associated with a shorter distance in the 6 MWT (standardized β = -0.249, p < 0.001) and a higher MLHFQ OSS (standardized β = 0.183, p-value = 0.008). In this study, we show that in patients with normal systemic iron parameters, higher levels of sTfR are strongly associated with an impaired submaximal exercise capacity and with worse QoL | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 6 min walking test (6MWT) | |
| 650 | 4 | |a Minnesota Living with Heart Failure Questionnaire (MLHFQ) | |
| 650 | 4 | |a heart failure | |
| 650 | 4 | |a iron deficiency | |
| 650 | 4 | |a quality of life | |
| 650 | 4 | |a soluble transferrin receptor | |
| 650 | 4 | |a submaximal functional capacity | |
| 700 | 1 | |a Ramos-Polo, Raúl |e verfasserin |4 aut | |
| 700 | 1 | |a Francesch Manzano, Josep |e verfasserin |4 aut | |
| 700 | 1 | |a Corbella Santano, Miriam |e verfasserin |4 aut | |
| 700 | 1 | |a Morillas Climent, Herminio |e verfasserin |4 aut | |
| 700 | 1 | |a Jose-Bazán, Núria |e verfasserin |4 aut | |
| 700 | 1 | |a Jiménez-Marrero, Santiago |e verfasserin |4 aut | |
| 700 | 1 | |a Garcimartin Cerezo, Paloma |e verfasserin |4 aut | |
| 700 | 1 | |a Yun Viladomat, Sergi |e verfasserin |4 aut | |
| 700 | 1 | |a Moliner Borja, Pedro |e verfasserin |4 aut | |
| 700 | 1 | |a Torres Cardús, Blanca |e verfasserin |4 aut | |
| 700 | 1 | |a Verdú-Rotellar, José Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Diez-López, Carles |e verfasserin |4 aut | |
| 700 | 1 | |a González-Costello, José |e verfasserin |4 aut | |
| 700 | 1 | |a García-Romero, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a de Frutos Seminario, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Triguero-Llonch, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Enjuanes Grau, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Tajes Orduña, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Comin-Colet, Josep |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of personalized medicine |d 2011 |g 13(2023), 8 vom: 21. Aug. |w (DE-627)NLM228113881 |x 2075-4426 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:8 |g day:21 |g month:08 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jpm13081282 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 8 |b 21 |c 08 | ||